Selection and Use of MySQL in a Database Management Course

This paper presents a case study of the selection and use of a software package for an introductory Database Management course in a typical MIS program. Teachers of Database Management face the challenge of providing their students with meaningful experiences with actual database software. The software selected for use in a database course can generally be categorized as one of three types: commercial enterprise software, such as Oracle or IBM’s DB2; personal database software, such as Microsoft Access; or software available for no cost (including open source software), such as PostgreSQL or MySQL. The advantages and disadvantages of each of these types of software are discussed, as is the selection process utilized in this specific case. The teaching approach examined in detail is the use of MySQL on a Linux platform to allow students to create, modify, populate, and query databases. This approach is shown to have several advantages: the software is available at no cost to the students or the institution; it is configurable and manageable by the course instructor without the need to consult specialized database professionals; it provides an enterprise database experience using Structured Query Language (SQL); and using the Internet, it is available to students from remote computers

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry1, James H Peace2, Jeanette A Stewart3,4, William C Stewart3,41Little Rock Eye Clinic, Little Rock, AR, USA; 2Diabetic Eye Medical Clinic, Inglewood, CA, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas,TX, USA; 4Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, USAPurpose: To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension.Design: Prospective, multi-center, historical control study.Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening. Patients were re-evaluated 3 months later.Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores compared to either latanoprost or bimatoprost (p < 0.0001). Patients having any baseline OSD symptoms (n = 235) demonstrated significant improvement after switching to travoprost BAK-free (p < 0.0001). In 70.2% of these patients, symptoms were reduced in severity by at least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure (IOP) was significantly decreased (p < 0.0001). Overall, 72.4% preferred travoprost BAK-free (p < 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p < 0.0001).Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control.Keywords: glaucoma, prostaglandin analog, travoprost, latanoprost, bimatoprost, preservative, benzalkonium chloride, ocular surface diseas

The Analysis of Commercially Available Kratom Products in Richmond, Virginia

Kratom is a novel psychoactive substance that has gained popularity within the past ten years. Originating from Southeast Asia, the leaves of the Mitragyna speciosa tree contain two principal alkaloids, mitragynine and 7-hydroxymitragynine, that play a key role in opioid-like effects. Twenty-nine kratom products were obtained from tobacco shops in the Richmond, Virginia area, including powders, teas, capsules, extracts, and a carbonated beverage. Samples were analyzed using Direct Analysis in Real Time-Mass Spectrometry (DART-MS) for kratom alkaloids, labeled ingredients, and other possible organic compounds. Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES) was used to quantitate aluminum, arsenic, copper, iron, magnesium, nickel, and lead with yttrium as the internal standard. Mitragynine and 7-hydroxymitragynine were present in every kratom sample. Kratom tea samples were found to have up to 20 times the tolerable upper intake of manganese. Overexposure to manganese can lead to Parkinsonian symptoms including tremors, dystonia, and facial muscle spasms. Gas Chromatography-Mass Spectrometry (GC-MS) was used to qualitatively confirm the presence of alkaloids and differentiate diastereomers. One non-kratom product was analyzed and was found to contain phenibut, an anxiolytic and nootropic substance. Phenibut was not listed on the label of this product. This work contributes to bring attention to the absence of quality control standards on kratom manufacturers as well as proper labeling of products sold at smoke and tobacco shops, prompting a public health concern due to the association of toxic metal levels in commercial kratom products.https://scholarscompass.vcu.edu/gradposters/1175/thumbnail.jp

Systematic prey preference by introduced mice exhausts the ecosystem on Antipodes Island

For assistance collecting samples in the field the authors thank David Thompson, Erica Sommer, David Boyle and Mark Fraser in summer 2011, Helen Nathan, Terry Greene and Graeme Elliott in winter 2013, Fin Cox in autumn 2016 and Jose Luis Herrera in winter 2016. Thanks to the Department of Conservation, Murihiku, for logistical support, and Hank Haazen and crew of the Tiama for transport. Funding was provided for the summer 2011 expedition by NIWA and winter 2013 expedition by the National Geographic Society (Grant No. 9322-13). Thanks to Stephen Thorpe, Robert Hoare, and John Marris for taxonomic identification of invertebrate samples. Thanks to Surrya Khanam for laboratory sorting, Julie Brown and Anna Kilimnik for stable isotope laboratory analyses and Wendy Nelson for macroalgae identification. JCR is currently funded by the Royal Society of New Zealand Rutherford Discovery Fellowship (Grant No. RDF-UOA1404). TWB is currently funded by the European Union's Horizon 2020 research and innovation programme Marie Skłodowska-Curie Fellowship (Grant No. 747120). Thanks to Katherine Russell and two anonymous reviewers for feedback on the manuscript. This research was conducted under DOC entry (SO-29716-LND 1011/35) and research (SO-29140-FAU 1011/20) permits, and University of Auckland Animal Ethics Committee approval (R845).Peer reviewedPublisher PD

A Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Latanoprost 0.005% and Timolol 0.5% Dosed Concomitantly in Patients with Open-Angle Glaucoma or Ocular Hypertension

Background/Aims: To compare the intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% in fixed combination with the unfixed combination of latanoprost 0.005% and timolol 0.5% in open-angle glaucoma or ocular hypertension patients with IOP levels below 18 mmHg on the unfixed combination of latanoprost 0.005% and timolol 0.5%. Methods: Following a 30-day open-label run-in with latanoprost QD PM and timolol QD AM, subjects with intraocular pressure below 18 mmHg were randomized to continue concomitant latanoprost QD PM and timolol QD AM or switch to travoprost 0.004%/timolol 0.5% QD AM and vehicle QD PM in masked fashion and were followed for 3 months. The primary efficacy endpoint was mean IOP reduction from baseline. Results: There were no clinically relevant or statistically significant differences in mean IOP, mean IOP change from baseline, or percentage IOP change from baseline between the two treatment groups. Between-group differences in mean IOP were within ±0.3 mmHg at all time points (p ≥ 0.384), and between-group differences in mean IOP change from baseline were within ±0.4 mmHg at all time points. Overall, 88% of patients whose IOP was less than 18 mmHg on the unfixed combination of latanoprost and timolol remained well controlled on the same regimen in the masked portion of the study, compared with 92% who remained well controlled after switching to travoprost/timolol. Conclusion: Travoprost 0.004%/timolol 0.5% administered once daily and concomitant administration of timolol 0.5% and latanoprost 0.005% produce similar maintenance of IOP-lowering effect in patients who were previously well controlled on concomitant administration of latanoprost and timolol. Patients who are well controlled on latanoprost and timolol concomitant therapy can be switched to once-daily therapy with travoprost 0.004%/timolol 0.5% with no expected compromise in the safety and efficacy of their treatment

Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.

PURPOSE: To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT). DESIGN: Prospective, randomized, double-masked, parallel-group, noninferiority clinical trial. METHODS: Adults with OAG or OHT from 46 clinical sites (United States and European Union) were randomized 2:1 to LBN instilled once daily (QD) in the evening and vehicle in the morning or timolol instilled twice a day (BID) for 3 months. IOP was measured at week 2, week 6, and month 3 (8 AM, 12 PM, and 4 PM each visit). RESULTS: A total of 387 subjects (LBN, n = 259; timolol, n = 128) completed the study. Analysis of covariance showed that mean IOP reduction with LBN was not only noninferior to timolol but significantly greater (P ≤ .025) than timolol at all but the first time point in this study (week 2, 8 AM). Of LBN- and timolol-treated subjects, respectively, 31.0% and 18.5% (P = .007) had their IOP reduced ≥25% from baseline, and 17.7% and 11.1% (P = .084) had their IOP reduced to ≤18 mm Hg over all time points/visits in this study. Ocular treatment-emergent adverse events, while uncommon, appeared more frequently in the LBN group (all mild-moderate except 1 case of severe hyperemia). CONCLUSIONS: LBN 0.024% QD in the evening was noninferior to timolol 0.5% BID over 3 months of treatment, with significantly greater IOP lowering in subjects with OAG or OHT at all but the earliest time point evaluated, and demonstrated a good safety profile